Why is Outlook Therapeutics stock surging today?
© Pavlo Gonchar / SOPA Images/Sipa via Reuters Connect Investing.com -- Outlook Therapeutics stock surged roughly 8.9% in pre-open trading after investors continued to pile into the name following the FDA’s approval of LYTENAVA (bevacizumab-vikg) for neovascular age-related macular degeneration, a decision that arrived on July 24 — two business days ahead of the official July 29 PDUFA target date. The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States, a distinction the company had been pursuing through multiple regulatory cycles, including a successful formal dispute resolution appeal earlier this year that cleared the path for resubmission without additional clinical trials.
Reported by 1 outlet — Investing.com · Stock Market. See all sources ↓
© Pavlo Gonchar / SOPA Images/Sipa via Reuters Connect Investing.com -- Outlook Therapeutics stock surged roughly 8.9% in pre-open trading after investors continued to pile into the name following the FDA’s approval of LYTENAVA (bevacizumab-vikg) for neovascular age-related macular degeneration, a decision that arrived on July 24 — two business days ahead of the official July 29 PDUFA target date. The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States, a distinction the company had been pursuing through multiple regulatory cycles, including a successful formal dispute resolution appeal earlier this year that cleared the path for resubmission without additional clinical trials. The regulatory milestone was quickly followed by a meaningful analyst catalyst: BTIG upgraded the stock from Neutral to Buy and assigned a $4.00 price target, pointing to the approximately $8.5 billion U.S. anti-VEGF retina market as the commercial opportunity ahead.
Read the full report at Investing.com · Stock Market ↗
Why it matters
A world story we're tracking; its significance and source trust firm up as more outlets confirm it.
- What's the story?
- © Pavlo Gonchar / SOPA Images/Sipa via Reuters Connect Investing.com -- Outlook Therapeutics stock surged roughly 8.9% in pre-open trading after investors continued to pile into the name following the FDA’s approval of LYTENAVA (bevacizumab-vikg) for neovascular age-related macular degeneration, a decision that arrived on July 24 — two business days ahead of the official July 29 PDUFA target date. The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD in the United States, a distinction the company had been pursuing through multiple regulatory cycles, including a successful formal dispute resolution appeal earlier this year that cleared the path for resubmission without additional clinical trials.
- How widely is it covered?
- 1 outlet, average source rating 6.0/10.
- When was it last updated?
- 4m ago.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
- Coverage card1 outlet1CoverageScouting report
Why is Outlook Therapeutics stock surging today?
Sources1TypeCoverageInvesting.com · Stock Market